[go: up one dir, main page]

MEP47308A - Hfa-suspension formulation of an anhydrate - Google Patents

Hfa-suspension formulation of an anhydrate

Info

Publication number
MEP47308A
MEP47308A MEP-473/08A MEP47308A MEP47308A ME P47308 A MEP47308 A ME P47308A ME P47308 A MEP47308 A ME P47308A ME P47308 A MEP47308 A ME P47308A
Authority
ME
Montenegro
Prior art keywords
anhydrate
hfa
suspension formulation
formulation
suspension
Prior art date
Application number
MEP-473/08A
Other languages
Croatian (hr)
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP47308A publication Critical patent/MEP47308A/en
Publication of ME00246B publication Critical patent/ME00246B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Pronalazak se odnosi na formulaciju, sa potisnim gasom, suspenzije, kristalnog anhidrata (1α,2β,4β,5α,7β)-7-[(hidroksidi-2-tienilacetil)oksi]-9,9-dimetil-3-oksa-9-azo-niatriciklo[3.3.1.02.4] nonan-bromida.The invention relates to the formulation, with propellant, of a suspension, of crystalline anhydrate (1α, 2β, 4β, 5α, 7β) -7 - [(hydroxides-2-thienylacetyl) oxy] -9,9-dimethyl-3-oxa-9 -azo-niatricyclo [3.3.1.02.4] nonan bromide.

MEP-2008-473A 2002-03-28 2003-03-20 HFA SUSPENSION FORMULATIONS OF AN ANHYDRATE ME00246B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (en) 2002-03-28 2002-03-28 HFA suspension formulations of an anhydrate
PCT/EP2003/002899 WO2003082244A2 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate

Publications (2)

Publication Number Publication Date
MEP47308A true MEP47308A (en) 2011-02-10
ME00246B ME00246B (en) 2011-05-10

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-473A ME00246B (en) 2002-03-28 2003-03-20 HFA SUSPENSION FORMULATIONS OF AN ANHYDRATE

Country Status (21)

Country Link
EP (1) EP1492498A2 (en)
JP (1) JP5147158B2 (en)
KR (1) KR101005717B1 (en)
CN (1) CN1642525A (en)
AU (1) AU2003221509B2 (en)
BR (1) BR0308709A (en)
CA (1) CA2479638C (en)
DE (1) DE10214264A1 (en)
EA (1) EA008610B1 (en)
EC (1) ECSP045322A (en)
HR (1) HRP20040890A2 (en)
IL (1) IL163696A0 (en)
ME (1) ME00246B (en)
MX (1) MXPA04009338A (en)
NO (1) NO20044004L (en)
NZ (1) NZ536030A (en)
PL (1) PL371295A1 (en)
RS (1) RS52481B (en)
UA (1) UA79776C2 (en)
WO (1) WO2003082244A2 (en)
ZA (1) ZA200405637B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563596A (en) * 2005-05-02 2011-01-28 Boehringer Ingelheim Int Crystalline form of tiotropium bromide anhydrate
EP1879888A2 (en) * 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
KR20120015334A (en) * 2009-05-29 2012-02-21 펄 테라퓨틱스 인코포레이티드 Compositions for Respiratory Delivery of Active Agents, and Associated Methods and Systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
ES2337554T3 (en) * 2000-10-31 2010-04-27 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG COMPOSITIONS OF MEDICINES BASED ON SALTS OF TIOTROPY AND EPINASTINE FOR THE DISEASE THERAPY OF THE RESPIRATORY ROADS.
DE10113366A1 (en) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist
DE10111058A1 (en) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and NK¶1¶ receptor antagonists

Also Published As

Publication number Publication date
CA2479638C (en) 2011-01-04
IL163696A0 (en) 2005-12-18
BR0308709A (en) 2005-01-04
ECSP045322A (en) 2005-01-28
KR101005717B1 (en) 2011-01-05
KR20040098022A (en) 2004-11-18
WO2003082244A2 (en) 2003-10-09
NO20044004L (en) 2004-10-05
DE10214264A1 (en) 2003-10-16
ME00246B (en) 2011-05-10
MXPA04009338A (en) 2005-01-25
EA008610B1 (en) 2007-06-29
CA2479638A1 (en) 2003-10-09
CN1642525A (en) 2005-07-20
YU86004A (en) 2006-08-17
NZ536030A (en) 2006-07-28
AU2003221509A1 (en) 2003-10-13
ZA200405637B (en) 2005-07-27
HRP20040890A2 (en) 2005-06-30
RS52481B (en) 2013-02-28
JP5147158B2 (en) 2013-02-20
JP2005527550A (en) 2005-09-15
PL371295A1 (en) 2005-06-13
WO2003082244A3 (en) 2004-02-05
AU2003221509B2 (en) 2008-01-24
UA79776C2 (en) 2007-07-25
EA200401159A1 (en) 2005-04-28
EP1492498A2 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
EA200401142A1 (en) MICRONIZED CRYSTALLINE TIOTROPYBROMID
EA200300666A1 (en) METHOD OF OBTAINING OWNER OF ANTICHOLINERGIC ACTION OF THIOTROPYBROMID
TW200617007A (en) Crystalline anticholinergic and its use for preparing a pharmaceutical composition
YU27303A (en) Crystalline monohydrate, mehod for producing the same and the use thereof in the production of a medicament
GT199900055A (en) NEW DIETHYDROPYRIMIDINES2 HETEROCYCLICALLY SUBSTITUTED.
ECSP055807A (en) QUINOLINILPIRROLOPIRAZOLES
AU2002229650A1 (en) Method for producing the anticholinergic agent tiotropium bromide
TW200738672A (en) Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
ES2137486T3 (en) DERIVATIVES OF 9-HYDROXY-PIRIDO (1,2-A) PIRIMIDIN-4-ONA-ETER.
MEP47308A (en) Hfa-suspension formulation of an anhydrate
PE20011289A1 (en) ANTIHELMINE COMPOSITIONS INCLUDING MACROCYCLIC AND SPIRODIOXEPINOINDOLES LACTONES
AR039670A1 (en) DERIVATIVES OF 1,2,3,4,7,8-HEXAHIDRO-6H- [1,4] DIAZEPINO [6,7,1J] QUINOLINE AS ANTIPSYTICAL AND ANTIOBESITY AGENTS
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
ES2158345T3 (en) DERIVATIVES OF PIPERAZINO AS ANTAGONISTS OF NEUROQUININA.
MEP47408A (en) Hfa-suspension formulations containing an anticholinergic
DK0414529T3 (en) Substituted steroid derivatives
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
ECSP045096A (en) HETEROARILO DERIVATIVES AS SUPERIOR LIGANDS FOR THE NOCICEPTIN RECEIVER ORL-1 "
PT1151360E (en) REALIZATION PROCESS USING A GLOBAL POSITIONING SYSTEM
UA86031C2 (en) Use of scopine ester derivatives as as a starting compound for preparing pharmacologically useful compounds
ES2090345T3 (en) DERIVATIVES OF 3- (SUBSTITUTED PIRAZOIL IN POSITION 1) -2-OXINDOL.
WO2007038250A3 (en) 1,25 - dihydroxy, 20-cyclopropyl, 26-27- deuteroalkyl vitamin d3 compounds and methods of use thereof
AR122179A1 (en) PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
HU0003661D0 (en) Thermofixation technology for stratificated polyolephine foil and method for fabrication of it using standing velve and/or support pillowing method
GT198302808A (en) PREFABRICATED CONCRETE HOUSE FOR GARITA USE